-
Product Insights
Endometriosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Endometriosis - Drugs In Development, 2023’, provides an overview of the Endometriosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis in Post Menopausal Osteoporosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis in Post Menopausal Osteoporosis Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dihydroergotamine Mesylate (Dhe) in Migraine
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dihydroergotamine Mesylate (Dhe) in Migraine report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Dihydroergotamine Mesylate (Dhe) in MigraineDrug Details:Dihydroergotamine mesylate is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tobramycin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tobramycin Drug Details Tobramycin (PIMS-954) is under development for the treatment of cystic fibrosis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – tobramycin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry tobramycin Drug Details Tobramycin is under development for the treatment of uncomplicated urinary tract...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Recombinant Peptide to Agonize PTH-R for Post Menopausal Osteoporosis Drug Details PTH analog is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – leuprolide
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry leuprolide Drug Details Leuprolide is under development for the treatment of endometriosis. The drug...